By characterising the circadian clock's role in ovarian cancer treatment, we aim to explore the potential mechanisms through which chronotherapy may contribute to reduced toxicity and improved quality of life in patients undergoing this therapy. This evidence concerns the gene CLOCK and ovarian carcinoma.